FOLH1 and prostate carcinoma: All different structures of anti-PSMA/anti-CD3 BsAb were specifically bonded to PSMA+ prostate cancer cells (LNCaP) and CD3+ T cells (Jurkat) but not PSMA− CD3− fibroblasts (NIH/3T3) (Fig. 1C).